Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Con
about
FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cellsLoss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.A microarray platform-independent classification tool for cell of origin class allows comparative analysis of gene expression in diffuse large B-cell lymphomaNovel prognostic genes of diffuse large B-cell lymphoma revealed by survival analysis of gene expression data.Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.Biomarkers of HIV-associated Cancer.The significance of FOXP1 in diffuse large B-cell lymphoma.Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphomaPoor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategiesTetraspanin CD37 protects against the development of B cell lymphomaAssessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.A microRNA signature profile in EBV+ diffuse large B-cell lymphoma of the elderly.Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOPThe histological classification of diffuse large B-cell lymphomasPredicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosisAggressive B-cell lymphomas: how many categories do we need?DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphomaIdentification and validation of a two-gene expression index for subtype classification and prognosis in Diffuse Large B-Cell LymphomaClinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy.Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphomaClinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphomaEpstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age.Clear cell variant of diffuse large B-cell lymphoma: a case report and review of the literature.Genetic lesions in diffuse large B-cell lymphomasLoss of IRF8 Inhibits the Growth of Diffuse Large B-cell LymphomaAge cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphomaLectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functionsExpression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice.hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision MedicineDiffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing.The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classificationDoes cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review.Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyPrognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047
P2860
Q24304887-83366E14-42A9-4662-AD5F-DBC6F99F3011Q27853399-425BBB04-757C-4A71-BC33-638D3A1AA9A2Q30485971-40B688FC-524D-4B6E-83BB-1235F8E7605AQ31028064-8CC5D18E-7FD5-4040-9AE4-2567476C947CQ33406742-3F21AD47-C890-4652-A289-BD3A47CB842BQ33583294-FB6CDD66-E1A6-4A4F-86EF-C24FA5614EA4Q33856851-367B602A-96BE-4937-BB11-2FC91ADA17BCQ34047455-06E38DF2-3B62-4855-8AC7-BA52319D65B3Q34287747-9FDEB895-647F-4A9E-8B7E-541EC502B84CQ34390837-45872CA9-E5F6-45D1-BE88-E81E56E51176Q34509755-C48FF8C4-AC8D-48B1-8748-0E9DFFEC1369Q34543066-2E239A1A-D015-4943-95F7-475835C2F62FQ35067988-2C8522E6-0354-4AE8-AA9D-CE415C5AE28EQ35145270-F16445B4-8496-4F09-87AC-826A28546173Q35218051-EFB8DB07-7A27-4855-BEFF-E74311BB94C2Q35402899-F49A69CF-C9D9-48F8-A3CC-9A1C67F04C4EQ35419876-259B7453-E158-4888-A283-32893A4E9E13Q35527893-8157D9D2-B7E7-4D2B-800D-EEA5088F1DCCQ35568457-3FC11BDE-27F5-4FEE-82F3-B2EBBB6FC3EFQ35569017-DEC67164-DFF1-4637-90A6-FECE4BB9B2D9Q35656926-F43EB59F-2AD3-48F5-A610-26C6DA5B9854Q35742364-AE8CC8B9-B5F1-47DE-B2A3-4A605F85C61EQ35742367-C2B1A419-A9D1-4C88-A7DC-C007F5835443Q35755485-9A8B840D-3832-4CB9-BF2A-ED925FD0438AQ35797583-D04A7531-1C22-4D99-BB8B-006A5DD98555Q35880791-ACC03839-A209-4C59-BC50-DAD763CDA6F2Q35919576-DB66BB30-5B0A-4643-BBF5-9FB046F756C9Q35974341-FC35FD0C-2A6E-4EB4-9FF8-F87F28CA8FA5Q35978570-F8F5D012-CC72-45EB-B7FC-EB0310223C90Q35987244-F4727C6B-8A17-4221-A0FD-9C96DFF10B46Q36051184-646F997F-DBFA-47A7-8A3A-2B200AE9BD2AQ36060329-7A450DDF-697C-4372-94C7-910C940EC1B8Q36068948-788252A7-C59F-4BFF-AC3C-B5D4BED80A3CQ36152713-DC381055-0F92-4BC4-9EB4-4761180810D0Q36210487-6EDBD308-4804-4C0D-AEDA-2C3412C45612Q36280547-589A631F-8392-4EFA-85A2-24C8AD52500FQ36302961-9AD98736-830A-45B5-8B5A-9FE0AB81D9F0Q36395599-0BBCD059-2134-444B-A702-272722E0D6CBQ36414139-CFA907AE-1F78-4C94-B675-F6A348C70CE8Q36490052-B8F50E2A-1930-4827-BDF1-FA863398C372
P2860
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Con
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Comprehensive gene expression ...... ional DLBCL Rituximab-CHOP Con
@ast
Comprehensive gene expression ...... ional DLBCL Rituximab-CHOP Con
@en
type
label
Comprehensive gene expression ...... ional DLBCL Rituximab-CHOP Con
@ast
Comprehensive gene expression ...... ional DLBCL Rituximab-CHOP Con
@en
prefLabel
Comprehensive gene expression ...... ional DLBCL Rituximab-CHOP Con
@ast
Comprehensive gene expression ...... ional DLBCL Rituximab-CHOP Con
@en
P2093
P2860
P50
P356
P1433
P1476
Comprehensive gene expression ...... ional DLBCL Rituximab-CHOP Con
@en
P2093
A J M Ferreri
C E Bueso-Ramos
C H Dunphy
E S G d'Amore
P2860
P2888
P304
P356
10.1038/LEU.2012.83
P577
2012-03-22T00:00:00Z